Early investigational antibiotics for the treatment of acute exacerbations of chronic bronchitis

Expert Opin Investig Drugs. 2017 Mar;26(3):313-317. doi: 10.1080/13543784.2017.1283402. Epub 2017 Jan 25.

Abstract

Acute exacerbations in patients with chronic bronchitis are a leading cause of hospitalizations and death. Bacteria contribute significantly to such exacerbations. The aim of this review was to explore the potential role of investigational antibiotics in the treatment of these episodes. Areas covered: The available literature in PubMed database, in websites related to investigational drugs and in websites of the producing companies has been searched. The in vitro activity against pathogens involved in acute exacerbations of chronic bronchitis and the pharmacokinetic profile of antibiotics currently under development were taken into consideration for inclusion in the review. Expert opinion: Several novel antimicrobial agents have completed preclinical and Phase I studies and were well-tolerated. Further investigation is mandatory in order to evaluate their future in treatment of chronic bronchitis exacerbations and discover potential advantages compared to already approved antimicrobials.

Keywords: Bacterial exacerbations; chronic bronchitis; in vitro activity; novel antibiotics; pharmacokinetic profile.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Animals
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology
  • Bacterial Infections / pathology
  • Bronchitis, Chronic / drug therapy*
  • Bronchitis, Chronic / microbiology
  • Bronchitis, Chronic / pathology
  • Drug Design
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / pharmacokinetics
  • Drugs, Investigational / therapeutic use
  • Humans

Substances

  • Anti-Bacterial Agents
  • Drugs, Investigational